日本の日常臨床診療において、経口ベネトクラックス錠±静脈内（IV）注入によるリツキシマブを投与された慢性リンパ性白血病（CLL）成人患者における検出限界以下の微小残存病変（uMRD）の頻度を評価する研究

基本情報

NCT ID

NCT06362044

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

89

治験依頼者名

AbbVie

概要

Most cases of Chronic lymphocytic leukemia (CLL) remain an incurable disease with the goal of therapy being to improve quality of life and to prolong survival. This study will evaluate the participant's related outcomes and experience of CLL in adult participants who are treated in the Japan. Study participants will receive oral treatments of Venetoclax±Rituximab for CLL as prescribed by their study doctor in accordance with approved local label. Adult participants prescribed various treatments Venetoclax±Rituximab will be enrolled. Around 89 participants will be enrolled in the study in sites in Japan. Participants will receive oral venetoclax tablets ± intravenously (IV) infused rituximab treatments for CLL according to the approved local label. The overall study duration will be 27 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.

対象疾患

依頼者（Sponsor）

実施施設 (1)